A detailed history of Core First Bank & Trust transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Core First Bank & Trust holds 11,940 shares of BMY stock, worth $635,088. This represents 0.34% of its overall portfolio holdings.

Number of Shares
11,940
Previous 12,380 3.55%
Holding current value
$635,088
Previous $671,000 26.23%
% of portfolio
0.34%
Previous 0.42%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$40.25 - $52.99 $17,710 - $23,315
-440 Reduced 3.55%
11,940 $495,000
Q4 2023

Mar 18, 2024

SELL
$48.48 - $57.85 $30,396 - $36,271
-627 Reduced 4.82%
12,380 $635,000
Q3 2023

Dec 18, 2023

SELL
$57.89 - $64.73 $33,865 - $37,867
-585 Reduced 4.3%
13,007 $754,000
Q2 2023

Aug 07, 2023

SELL
$63.71 - $70.74 $14,334 - $15,916
-225 Reduced 1.63%
13,592 $869,000
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $59,138 - $67,077
-900 Reduced 6.12%
13,817 $957,000
Q4 2022

Feb 15, 2023

BUY
$68.48 - $81.09 $54,784 - $64,872
800 Added 5.75%
14,717 $1.06 Million
Q3 2022

Nov 16, 2022

SELL
$0.13 - $76.84 $0 - $153
-2 Reduced 0.01%
13,917 $989,000
Q2 2022

Aug 16, 2022

BUY
$72.62 - $79.98 $145,240 - $159,960
2,000 Added 16.78%
13,919 $1.07 Million
Q4 2021

Feb 10, 2022

SELL
$53.63 - $62.52 $12,871 - $15,004
-240 Reduced 1.97%
11,919 $743,000
Q3 2021

Nov 15, 2021

SELL
$59.17 - $69.31 $106,920 - $125,243
-1,807 Reduced 12.94%
12,159 $720,000
Q2 2021

Aug 17, 2021

BUY
$61.91 - $67.42 $5,386 - $5,865
87 Added 0.63%
13,966 $933,000
Q1 2021

May 18, 2021

SELL
$59.34 - $66.74 $23,736 - $26,695
-400 Reduced 2.8%
13,879 $876,000
Q4 2020

Feb 16, 2021

BUY
$57.74 - $65.43 $824,469 - $934,274
14,279 New
14,279 $886,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Core First Bank & Trust Portfolio

Follow Core First Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core First Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Core First Bank & Trust with notifications on news.